AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for FAD-linked sulfhydryl oxidase ALR

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P55789

UPID:

ALR_HUMAN

Alternative names:

Augmenter of liver regeneration; Hepatopoietin

Alternative UPACC:

P55789; Q53YM6; Q8TAH6; Q9H290; Q9UK40

Background:

FAD-linked sulfhydryl oxidase ALR, also known as Augmenter of liver regeneration and Hepatopoietin, plays a crucial role in mitochondrial function. It acts as a FAD-dependent sulfhydryl oxidase, essential for regenerating redox-active disulfide bonds in CHCHD4/MIA40. This process is vital for protein folding in the mitochondrial intermembrane space, highlighting ALR's significance in cellular health and energy production.

Therapeutic significance:

ALR's involvement in mitochondrial progressive myopathy, congenital cataract, hearing loss, and developmental delay underscores its therapeutic potential. Understanding the role of FAD-linked sulfhydryl oxidase ALR could open doors to potential therapeutic strategies for these conditions, offering hope for targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.